Array technology and proteomics in autoimmune diseases

Krenn, Veit; Petersen, Iver; Haeupl, Thomas; Koepenik, Axel; Blind, Christiane; Dietel, Manfred; Konthur, Zoltan; Skriner, Karl

doi:10.1016/j.prp.2004.02.005

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Array technology and proteomics in autoimmune diseases

MPS-Authors

Konthur, Zoltan
Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Krenn, V., Petersen, I., Haeupl, T., Koepenik, A., Blind, C., Dietel, M., et al. (2004). Array technology and proteomics in autoimmune diseases. Proteomics in Pathology, Research and Practice, 95-103. doi:10.1016/j.prp.2004.02.005.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-8861-6

Abstract

Two new technologies (tissue microarrays (TMAs) and proteomics) have generated a great amount of data in life science. High-density TMAs allow for the simultaneous analysis of proteins and RNA by various methods (immunohistochemistry, in situ hybridization, FISH) on a large scale and under highly standardized conditions. Proteomics includes a variety of techniques that are partly high throughput. These techniques aim at the innovation of proteins, the description of the domain structure, the determination of protein sequences and epitope characterization, and ultimately the definition of protein function and protein reactivities in immunologic processes. Proteins that have been characterized accordingly require validation mostly at the morphologic level of defined tissue, linking proteomics to TMAs. In autoimmune diseases, array-based antigenic fingerprinting of autoantibodies will drive the development and the selection of antigen-specific diagnostic tools and therapies. The powerful combination of genomics and proteomics formed in tissue arrays has the potential to change the way the biology of autoimmunity is studied. Novel targets of drug discovery, based on antigen-specific therapies to induce anergy, or regulatory T-cells using the targeted autoantigens of individual patients could be developed in the coming decades.